Orexo AB (publ)

May 19, 2020

Report From Orexo AB's Extraordinary General Meeting, 19 May 2020

Apr 16, 2020

James Noble Appointed as Chairman of the Board

Apr 09, 2020

The Board of Directors of Orexo Withdraws Proposal on Incentive Program

Apr 06, 2020

Orexo Ends Share Buy-back Program

Mar 06, 2020

Orexo Submits Application for vorvida® to the FDA to Enable Commercialization in the US

Dec 02, 2019

Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health

Nov 27, 2019

Orexo Acquires Exclusive US Rights to Commercialize Vorvida®, a Digital Therapy for Alcohol Use Disorder with Scientifically Proven Efficacy

Nov 08, 2019

Orexo to Present at Jefferies 2019 Healthcare Conference

Apr 11, 2019

Report from Orexo AB's Annual General Meeting

Jan 07, 2019

Positive Results From Human PK Study Assessing Orexo's New Intranasal Naloxone Formulations for Opioid Overdose Reversal

Oct 01, 2018

Orexo Internalizes Contract Field Force in the US to Further Strengthen the Commercial Organization

Apr 12, 2018

Report from Orexo AB's Annual General Meeting

Nov 30, 2017

Orexo Publishes Prospectus and Applies for Listing of Bonds on Nasdaq Stockholm